GlassScriptPhysician profile
Lindsey Whitaker Brown
NPI 1689330029
$1,149.86
in general payments reported to CMS, 2019-2025
19 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $76.86 · 2023: $150 · 2024: $485 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $257.09 | 2024-2025 | Fetroja |
| Astrazeneca Pharmaceuticals LP | $135.98 | 2023-2024 | Farxiga, Wainua |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.79 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $86.19 | 2024-2025 | Verquvo, Zerbaxa, Dificid |
| Pfizer INC. | $85.07 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $76.86 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $57.53 | 2023-2024 | Inpefa |
| Philips North America LLC | $51.48 | 2023-2024 | (Ck4) Mcot |
| Janssen Pharmaceuticals, INC | $48.65 | 2023-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $44.28 | 2024-2025 | Eliquis |
| Abbvie INC. | $44.20 | 2025 | |
| Irhythm Technologies, INC. | $33.38 | 2024 | Zio Xt Patch, Zio Monitor |
| Takeda Pharmaceuticals U.S.A., INC. | $26.50 | 2025 | Vpriv |
| Scpharmaceuticals INC. | $21.43 | 2024 | |
| Route 92 Medical, INC. | $18.60 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $18.35 | 2024 | Bodyguardian |
| Otsuka America Pharmaceutical, INC. | $18.01 | 2023 | Nuedexta |
| Regeneron Healthcare Solutions, INC. | $15.21 | 2024 | Evkeeza |
| Novartis Pharmaceuticals Corporation | $14.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.